The vaccine is delivered nasally and is a live-attenuated candidate for SARS-CoV-2, the company said. CDX-005 was engineered using the company's proprietary codon deoptimization software platform, which allowed them to recode the SARS-CoV-2 virus genome by inserting hundreds of mutations.

Preclinical animal studies have been successfully completed and a phase I human clinical trial will begin in the U.K. by the end of this year, according to Codagenix.

The Serum Institute, the world's largest supplier of vaccines globally at more than 1.5 billion doses, has begun manufacturing for large-scale safety and efficacy studies and to prepare to meet global vaccine supply requirements after receiving the necessary approval from the Review Committee on Genetic Manipulation of India's Department of Biotechnology.

Codagenix synthesizes live-attenuated COVID-19 vaccine
Codagenix has successfully synthesized a live-attenuated vaccine candidate for COVID-19 called CDX-005.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...